A case of elderly advanced squamous cell lung carcinoma successfully treated with nedaplatin and S-1 combination chemotherapy

Hideki Terai, Kenzo Soejima, Katsuhiko Naoki, Shinnosuke Ikemura, Hiromi Ogura-Tomomatsu, Takashi Sato, Koichiro Asano, Tomoko Betsuyaku

Research output: Contribution to journalArticle

Abstract

A 74-year-old male was referred to our hospital for an abnormal chest shadow pointed out by a medical examination. A chest computed tomography revealed a tumor shadow 39 X 32 mm in size in his left upper lobe in January, 2010. Pathological examination of biopsy specimens showed squamous cell carcinoma of the lung. Although there was no distant metastasis, multiple metastases to mediastinal lymph nodes was noted. He was diagnosed as Stage IIIA (cT2aN2M0). Considering his age and the histology of the disease, systemic chemotherapy with nedaplatin and S-1 was performed. The diameter of the primary lesion was decreased from 39 mm to 18 mm after 4 courses of chemotherapy, and was considered as partial response (PR) according to the RECIST criteria. The adverse events were grade 2 appetite loss, grade 3 neutropenia, and grade 2 thrombocytopenia. Recently, various new agents for treating non-squamous cell lung carcinoma have been developed, but there has been little progress in the treatment of squamous cell lung carcinoma. We experienced a patient with advanced squamous cell lung carcinoma who responded with CDGP/S-1 combination chemotherapy. We are now conducting a phase I / II clinical study to verify the usefulness of this regimen against advanced squamous cell lung carcinoma, S-1.

Original languageEnglish
Pages (from-to)429-432
Number of pages4
JournalJapanese Journal of Cancer and Chemotherapy
Volume39
Issue number3
Publication statusPublished - 2012 Mar

Fingerprint

Combination Drug Therapy
Squamous Cell Carcinoma
Lung
Thorax
Neoplasm Metastasis
Drug Therapy
Appetite
Neutropenia
Histology
Lymph Nodes
Tomography
S 1 (combination)
nedaplatin
Carcinoma
Biopsy
Neoplasms
Therapeutics

Keywords

  • Nedaplatin
  • S-1
  • Squamous cell lung carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A case of elderly advanced squamous cell lung carcinoma successfully treated with nedaplatin and S-1 combination chemotherapy. / Terai, Hideki; Soejima, Kenzo; Naoki, Katsuhiko; Ikemura, Shinnosuke; Ogura-Tomomatsu, Hiromi; Sato, Takashi; Asano, Koichiro; Betsuyaku, Tomoko.

In: Japanese Journal of Cancer and Chemotherapy, Vol. 39, No. 3, 03.2012, p. 429-432.

Research output: Contribution to journalArticle

Terai, Hideki ; Soejima, Kenzo ; Naoki, Katsuhiko ; Ikemura, Shinnosuke ; Ogura-Tomomatsu, Hiromi ; Sato, Takashi ; Asano, Koichiro ; Betsuyaku, Tomoko. / A case of elderly advanced squamous cell lung carcinoma successfully treated with nedaplatin and S-1 combination chemotherapy. In: Japanese Journal of Cancer and Chemotherapy. 2012 ; Vol. 39, No. 3. pp. 429-432.
@article{515aa34445a44b43b9e43ef9461ffdb0,
title = "A case of elderly advanced squamous cell lung carcinoma successfully treated with nedaplatin and S-1 combination chemotherapy",
abstract = "A 74-year-old male was referred to our hospital for an abnormal chest shadow pointed out by a medical examination. A chest computed tomography revealed a tumor shadow 39 X 32 mm in size in his left upper lobe in January, 2010. Pathological examination of biopsy specimens showed squamous cell carcinoma of the lung. Although there was no distant metastasis, multiple metastases to mediastinal lymph nodes was noted. He was diagnosed as Stage IIIA (cT2aN2M0). Considering his age and the histology of the disease, systemic chemotherapy with nedaplatin and S-1 was performed. The diameter of the primary lesion was decreased from 39 mm to 18 mm after 4 courses of chemotherapy, and was considered as partial response (PR) according to the RECIST criteria. The adverse events were grade 2 appetite loss, grade 3 neutropenia, and grade 2 thrombocytopenia. Recently, various new agents for treating non-squamous cell lung carcinoma have been developed, but there has been little progress in the treatment of squamous cell lung carcinoma. We experienced a patient with advanced squamous cell lung carcinoma who responded with CDGP/S-1 combination chemotherapy. We are now conducting a phase I / II clinical study to verify the usefulness of this regimen against advanced squamous cell lung carcinoma, S-1.",
keywords = "Nedaplatin, S-1, Squamous cell lung carcinoma",
author = "Hideki Terai and Kenzo Soejima and Katsuhiko Naoki and Shinnosuke Ikemura and Hiromi Ogura-Tomomatsu and Takashi Sato and Koichiro Asano and Tomoko Betsuyaku",
year = "2012",
month = "3",
language = "English",
volume = "39",
pages = "429--432",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "3",

}

TY - JOUR

T1 - A case of elderly advanced squamous cell lung carcinoma successfully treated with nedaplatin and S-1 combination chemotherapy

AU - Terai, Hideki

AU - Soejima, Kenzo

AU - Naoki, Katsuhiko

AU - Ikemura, Shinnosuke

AU - Ogura-Tomomatsu, Hiromi

AU - Sato, Takashi

AU - Asano, Koichiro

AU - Betsuyaku, Tomoko

PY - 2012/3

Y1 - 2012/3

N2 - A 74-year-old male was referred to our hospital for an abnormal chest shadow pointed out by a medical examination. A chest computed tomography revealed a tumor shadow 39 X 32 mm in size in his left upper lobe in January, 2010. Pathological examination of biopsy specimens showed squamous cell carcinoma of the lung. Although there was no distant metastasis, multiple metastases to mediastinal lymph nodes was noted. He was diagnosed as Stage IIIA (cT2aN2M0). Considering his age and the histology of the disease, systemic chemotherapy with nedaplatin and S-1 was performed. The diameter of the primary lesion was decreased from 39 mm to 18 mm after 4 courses of chemotherapy, and was considered as partial response (PR) according to the RECIST criteria. The adverse events were grade 2 appetite loss, grade 3 neutropenia, and grade 2 thrombocytopenia. Recently, various new agents for treating non-squamous cell lung carcinoma have been developed, but there has been little progress in the treatment of squamous cell lung carcinoma. We experienced a patient with advanced squamous cell lung carcinoma who responded with CDGP/S-1 combination chemotherapy. We are now conducting a phase I / II clinical study to verify the usefulness of this regimen against advanced squamous cell lung carcinoma, S-1.

AB - A 74-year-old male was referred to our hospital for an abnormal chest shadow pointed out by a medical examination. A chest computed tomography revealed a tumor shadow 39 X 32 mm in size in his left upper lobe in January, 2010. Pathological examination of biopsy specimens showed squamous cell carcinoma of the lung. Although there was no distant metastasis, multiple metastases to mediastinal lymph nodes was noted. He was diagnosed as Stage IIIA (cT2aN2M0). Considering his age and the histology of the disease, systemic chemotherapy with nedaplatin and S-1 was performed. The diameter of the primary lesion was decreased from 39 mm to 18 mm after 4 courses of chemotherapy, and was considered as partial response (PR) according to the RECIST criteria. The adverse events were grade 2 appetite loss, grade 3 neutropenia, and grade 2 thrombocytopenia. Recently, various new agents for treating non-squamous cell lung carcinoma have been developed, but there has been little progress in the treatment of squamous cell lung carcinoma. We experienced a patient with advanced squamous cell lung carcinoma who responded with CDGP/S-1 combination chemotherapy. We are now conducting a phase I / II clinical study to verify the usefulness of this regimen against advanced squamous cell lung carcinoma, S-1.

KW - Nedaplatin

KW - S-1

KW - Squamous cell lung carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84861540363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861540363&partnerID=8YFLogxK

M3 - Article

VL - 39

SP - 429

EP - 432

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 3

ER -